Nebenwirkungen · Celsentri
CELSENTRI 20 mg/mL oral solution · Abschnitt 4.8 · PDF-Seite 42
HOS-118528 · Präparat HOS-094825
The MOTIVATE studies were extended beyond 96 weeks, with an observational phase extended to 5 years in order to assess the long-term safety of maraviroc. The Long-Term Safety/Selected Endpoints (LTS/SE) included death, AIDS-defining events, hepatic failure, Myocardial infarction/cardiac ischaemia, malignancies, rhabdomyolysis and other serious infectious events with maraviroc treatment. The incidence of these selected endpoints for subjects on maraviroc in this observational phase was consistent with the incidence seen at earlier timepoints in the studies.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 5da143fe721e3f0e0d1d6166da98dabf4ac76dd38459c3453bbb17c3f2b1a252 · Zeichen 6552–7114 im Abschnitt